

ANNOUNCEMENT

The Board of Directors of Malaysian Genomics Resource Centre Berhad (hereinafter referred to as "MGRC" or "the Company") and its subsidiaries ("the Group") hereby announce the following unaudited results for the second quarter ended 30 June 2026.

A PRESENTATION OF RESULTS

I CONDENSED STATEMENT OF PROFIT AND LOSS AND OTHER COMPREHENSIVE INCOME

	Individual Quarter		Year-to-Date	
	Current	Previous	Current	Previous
	Period	Period	Period	Year
for the financial period ended	30.6.2026	30.6.2025	30.6.2026	30.6.2025
	(RM'000)	(RM'000)	(RM'000)	(RM'000)
Continuing operations				
Revenue	2,550	1,796	5,204	3,145
Cost of sales	(549)	(608)	(817)	(1,017)
Gross profit	2,001	1,188	4,387	2,128
Other income	90	1	120	5
Marketing and distribution	(36)	(26)	(64)	(40)
Finance cost	(19)	(25)	(39)	(51)
Administrative expenses	(1,437)	(1,586)	(2,724)	(3,317)
Profit/(Loss) before taxation	599	(448)	1,680	(1,275)
Taxation	-	-	-	-
Profit/(Loss) for the period/Total comprehensive income/(loss) for the period/year	599	(448)	1,680	(1,275)
Profit/(Loss) attributable to:				
Owners of the parent	660	(370)	1,800	(1,118)
Non-controlling interests	(61)	(78)	(120)	(157)
Profit/(Loss) for the period/Total comprehensive income/(loss) for the period/year	599	(448)	1,680	(1,275)
Total comprehensive income/(loss) attributable to:				
Owners of the parent	660	(370)	1,800	(1,118)
Non-controlling interests	(61)	(78)	(120)	(157)
Total comprehensive income/(loss) for the period/year	599	(448)	1,680	(1,275)
Earning/(Loss) per share EPS/(LPS) attributable to the equity holders of the Company (sen)				
Basic EPS/(LPS)	0.44	(0.27)	1.22	(0.81)
Diluted EPS/(LPS)	N/A	N/A	N/A	N/A

The unaudited condensed statement of profit and loss and other comprehensive income should be read in conjunction with the audited financial statements for the financial year ended 31 December 2025 and the accompanying explanatory notes that form an integral part of the Interim Financial Statements.

Notes:-

There is no income/expense in relation to other income including investment income, gain/loss on disposal of quoted or unquoted investments or properties, gain/loss on derivatives, or exceptional items, except for as disclosed on the cashflow statement.

A PRESENTATION OF RESULTS (cont.)

II CONDENSED STATEMENT OF FINANCIAL POSITION

as at	30.6.2026 (RM'000)	31.12.2025 (RM'000)
ASSETS		
NON-CURRENT ASSETS		
Plant and equipment	1,926	2,140
Intangible assets	3,247	3,458
Right-of-use assets	919	1,064
Other investment	2,500	2,500
	<u>8,592</u>	<u>9,162</u>
CURRENT ASSETS		
Trade and other receivables	7,812	7,907
Inventories	771	390
Other current assets	235	191
Tax recoverable	254	40
Cash and bank balances	4,307	1,019
	<u>13,379</u>	<u>9,547</u>
TOTAL ASSETS	<u>21,971</u>	<u>18,709</u>
EQUITY AND LIABILITIES		
EQUITY		
Share capital	19,852	17,436
Retained earnings/(Accumulated losses)	138	(1,662)
Equity attributable to the owners of the company	<u>19,990</u>	<u>15,774</u>
Non-controlling interest	(1,110)	(990)
TOTAL EQUITY	<u>18,880</u>	<u>14,784</u>
LIABILITIES		
NON-CURRENT LIABILITY		
Lease liabilities	760	921
	<u>760</u>	<u>921</u>
CURRENT LIABILITIES		
Trade and other payables	1,983	2,673
Contract liabilities	32	26
Lease liabilities	316	305
	<u>2,331</u>	<u>3,004</u>
TOTAL LIABILITIES	<u>3,091</u>	<u>3,925</u>
TOTAL EQUITY AND LIABILITIES	<u>21,971</u>	<u>18,709</u>
Net assets (RM'000)	19,990	15,774
Net assets per share attributable to equity holders of the Company (sen)	13.24	11.50

The unaudited condensed statement of financial position should be read in conjunction with the audited financial statements for the financial year ended 31 December 2025 and the accompanying explanatory notes that form an integral part of the Interim Financial Statements.

A PRESENTATION OF RESULTS (cont.)

III CONDENSED STATEMENT OF CHANGES IN EQUITY

	Equity, Total	Non Distributable Share Capital	(Accumulated Losses)/ Retained Earnings	Non- Controlling Interest
for the financial period ended 30 June 2026	(RM'000)	(RM'000)	(RM'000)	(RM'000)
Opening balance at 1 January 2026	14,784	17,436	(1,662)	(990)
Total comprehensive income/(loss)	1,680	-	1,800	(120)
Issuance of new shares, net of share issuance expenses	2,416	2,416	-	-
Closing balance at 30 June 2026	18,880	19,852	138	(1,110)
for the financial period ended 31 December 2025	(RM'000)	(RM'000)	(RM'000)	(RM'000)
Opening balance at 1 January 2025	17,573	59,436	(41,280)	(583)
Total comprehensive loss	(2,798)	-	(2,382)	(416)
Share capital reduction	-	(42,000)	42,000	-
Elimination of non-controlling interest at disposal of subsidiary	9	-	-	9
Closing balance at 31 December 2025	14,784	17,436	(1,662)	(990)

The unaudited condensed statement of changes in equity should be read in conjunction with the audited financial statements for the financial year ended 31 December 2025 and the accompanying explanatory notes that form an integral part of the Interim Financial Statements.

A PRESENTATION OF RESULTS (cont.)
IV CONDENSED STATEMENT OF CASH FLOWS

for the financial period ended	Year-to-Date	
	Current Year	Previous Year
	30.6.2026 (RM'000)	30.6.2025 (RM'000)
Cash flows from operating activities		
Profit/(Loss) before tax	1,680	(1,275)
Adjustments for:		
Amortisation of intangible assets	211	210
Depreciation of plant and equipment	298	347
Depreciation of right-of-use assets	145	190
Interest expenses	39	51
Operating profit before working capital changes	2,373	(477)
Decrease in receivables	51	694
(Increase)/Decrease in inventories	(381)	136
Decrease in payables	(684)	(218)
Cash generated from operations	1,359	135
Tax paid	(214)	(67)
Interest paid	(39)	(49)
Net cash generated from operating activities	1,106	19
Cash flows from investing activity		
Purchase of plant and equipment	(84)	(8)
Net cash used in investing activity	(84)	(8)
Cash flows from financing activities		
Proceeds from issuance of shares, net of share issuance expenses	2,416	-
Repayment of lease liabilities	(150)	(140)
Net cash generated from/(used in) financing activities	2,266	(140)
Net increase/(decrease) in cash and cash equivalents	3,288	(129)
Cash and cash equivalents at beginning of the period	1,019	271
Cash and cash equivalents at end of period	4,307	142

The unaudited condensed statement of cash flows should be read in conjunction with the audited financial statements for the financial year ended 31 December 2025 and the accompanying explanatory notes that form an integral part of the Interim Financial Statements.

UNAUDITED NOTES TO THE INTERIM FINANCIAL STATEMENTS
B Explanatory Notes Pursuant to MFRS 134
i Basis of Preparation

These condensed consolidated interim financial statements have been prepared in accordance with MFRS 134 Interim Financial Reporting, and Rule 9.22 and Appendix 9B of the ACE Market Listing Requirements ("Listing Requirements") of Bursa Malaysia Securities Berhad ("Bursa Malaysia").

This report should be read in conjunction with the audited financial statements for the financial year ended 31 December 2025 and the accompanying explanatory notes as disclosed in the Annual Report issued on 30 April 2026. The significant accounting policies adopted in preparing these condensed consolidated interim financial statements are consistent with those of the audited financial statements for the financial year ended 31 December 2025.

ii Significant Accounting Policies

The significant accounting policies adopted by the Group in this interim financial report are consistent with those adopted in preparation of the Group's financial statements for the financial year ended 31 December 2025, except for the following new MFRSs and amendments to MFRSs that have been issued by the MASB.

a. MFRSs, Amendments to MFRSs and Interpretations adopted

For the preparation of the financial statements, the following accounting standards and amendments of the MFRS framework issued by the MASB are mandatory for the first time for the current financial year:

MFRSs, Amendments to MFRSs and IC Interpretations	Effective for financial periods beginning on or after
Amendments to MFRS 9, Financial Instruments and MFRS 7, Financial Instruments: Disclosures – Classification and Measurement of Financial Instruments	1 January 2026
Amendments to MFRS 1, First-time Adoption of Malaysian Financial Reporting Standards - Annual Improvements – Volume 11	1 January 2026
Amendments to MFRS 7 and MFRS 9 Financial Instruments: Disclosure - Annual Improvements - Volume 11	1 January 2026
Amendments to MFRS 10 Consolidated Financial Statements - Annual Improvements - Volume 11	1 January 2026
Amendments to MFRS 107 Statement of Cash Flows - Annual Improvements - Volume 11	1 January 2026
Amendments to MFRS 7 and MFRS 9 Financial Instruments: Contracts Referencing Nature-dependent Electricity	1 January 2026

The adoption of the abovementioned accounting standards and amendments are not expected to have any material impact on the financial statements of the Group.

B Explanatory Notes Pursuant to MFRS 134 (cont.)
ii Significant Accounting Policies (cont.)
b. Amendments to MFRSs not adopted

As at the date of authorisation of the unaudited interim financial report, the following standards and amendments to standards were issued but not yet effective and have not been adopted by the Group:

MFRSs, Amendments to MFRSs and IC Interpretations	Effective for financial periods beginning on or after
MFRS 18, Presentation and Disclosure in Financial Statements	1 January 2027
MFRS 19, Subsidiaries without Public Accountability: Disclosures	1 January 2027
Amendments to MFRS 19 Subsidiaries without Public Accountability: Disclosures	1 January 2027
Amendments to MFRS 121 The Effects of Changes in Foreign Exchange Rates – Translation to a Hyperinflationary Presentation Currency	1 January 2027
Amendments to MFRS 10, “Consolidated Financial Statements” and MFRS 128, “Investments in Associates and Joint Ventures” (Sale or Contribution of Assets between an	Deferred until further notice

The initial application of the above mentioned accounting standards, amendments or interpretations are not expected to have any material impact to the financial statements of the Group upon adoption.

iii Auditors’ Report on Preceding Annual Financial Statements

The auditor opinion of audited financial statements for the financial year ended 31 December 2025 were not qualified.

iv Seasonal and Cyclical Factors

The operations of MGRC were not significantly affected by seasonal and cyclical factors.

v Material and Unusual Items Affecting Assets, Liabilities, Equity, Net Income or Cash Flow

There were no material and unusual items affecting assets, liabilities, equity, net income or cash flows during the financial period.

vi Material Changes in Estimates

There were no material changes in the estimates that had effect(s) on the financial period.

vii Debt and Equity Securities

There were no issues, repurchases and repayments of debt and equity securities for the financial period to date.

viii Dividends Paid

There were no dividends paid for the financial period.

ix Segmental Information

MFRS 8 requires identification of reporting segment on the basis of internal reports that are regularly reviewed by the entity's Executive Directors in order to allocate resources to the segment and assess its performance. The management monitors the operating results of the Group as a whole for the purpose of making decisions about resource allocation and performance assessment. Accordingly, the Group has only one reportable segment for the period under review as well as the foreseeable future. Please refer to the financial statements presented in Part A of this announcement.

x Valuation of Plant and Equipment

There has been no valuation made on any of the Group's plant and equipment during the current financial period under review.

B Explanatory Notes Pursuant to MFRS 134 (cont.)
xi Subsequent Events

There were no material events subsequent to the end of the current financial period under review that have not been reflected.

xii Changes in the Composition of the Group

There were no changes to the composition of the Group in the current quarter under review.

xiii Contingent Liabilities or Contingent Assets

There was no contingent liability or contingent asset arising since the last audited statement of financial position as at 31 December 2025.

xiv Capital Commitments

The company has material capital commitments at the end of the financial period as follow:-

	Current Year	Previous Year
	30.6.2026	30.6.2025
	(RM'000)	(RM'000)
Approved but not contracted for:		
Purchase of others	81	25
Services	-	132
	<u>81</u>	<u>157</u>

xv Related Party Transactions

Save as disclosed below, the related party transactions during the financial period to date:-

for the financial period ended		Individual Quarter		Year-to-Date	
		Current Year	Previous Year	Current Year	Previous Year
		30.6.2026	30.6.2025	30.6.2026	30.6.2025
Related Party	Nature of Transaction	(RM'000)	(RM'000)	(RM'000)	(RM'000)
Aquahealth Sdn Bhd	Interest	37	37	74	74
		<u>37</u>	<u>37</u>	<u>74</u>	<u>74</u>

xvi Cash and Cash Equivalents

as at

	Current Year	Previous Year
	30.6.2026	30.6.2025
	(RM'000)	(RM'000)
Cash on hand and at banks	<u>4,307</u>	<u>142</u>

The Group's cash and cash equivalents increased significantly by RM4.17 million from RM0.14 million to RM4.31 million as compared to the previous financial period. This was mainly due to the proceeds received from the private placement exercise as well as improved cash inflows generated from the Group's business operations during the period.

xvii Inventories

There was no write-down of inventories during the financial period to date.

C Explanatory Notes Pursuant to Appendix 9B, of the Listing Requirements

These condensed consolidated interim financial statements, for the financial period ended 30 June 2026, have been prepared in accordance with Rule 9.22 and Appendix 9B of the Listing Requirements.

i Performance of the Group

for the financial period ended	Individual Quarter		Year-to-Date	
	Current Year	Previous Year	Current Year	Previous Year
	30.6.2026 (RM'000)	30.6.2025 (RM'000)	30.6.2026 (RM'000)	30.6.2025 (RM'000)
Revenue	2,550	1,796	5,204	3,145
Profit/(loss) before tax	599	(448)	1,680	(1,275)

Current Year Quarter End versus Previous Year 2nd Quarter

For the quarter ended 30 June 2026, the Group recorded revenue of RM2.55 million, representing an increase of RM0.75 million compared to revenue of RM1.80 million recorded in the second quarter of the preceding year. The increase was mainly attributable to higher demand for the Group's cell therapies and immunotherapies segment, following the introduction of more attractive pricing packages and the Group's continued marketing efforts.

The Group intensified its marketing efforts through participation in workshops and events as well as the use of social media platforms to enhance brand visibility and product awareness. These initiatives helped to expand the Group's market reach and customer engagement, supporting the growth in demand and contributing to the improved revenue performance during the quarter.

For the current quarter, the Group recorded a profit before tax of RM0.60million as compared to a loss before tax of RM0.45million in the corresponding quarter of the preceding year. The improvement in financial performance was mainly attributable to higher revenue contribution from the Group's business operations.

Current Year-to-Date versus Previous Year-to-Date

The Group recorded a revenue of RM5.20million, representing an increased of RM2.05million as compared to a revenue of RM3.15million in the corresponding period of the preceding year. The increase was mainly attributable to higher demand for the Group's cell therapies and immunotherapies segment, driven by the introduction of more attractive pricing packages and marketing efforts undertaken by the Group.

The Group recorded a profit before tax of RM1.68 million compared to loss before tax of RM1.28 million in the corresponding period of the preceding year, primarily attributable to increased revenue and cost savings. This demonstrates the effectiveness of the cost-saving initiatives implemented by the Group.

C Explanatory Notes Pursuant to Appendix 9B, of the Listing Requirements (cont.)
ii Comparison with Preceding Quarter's Results

The comparison of this quarter's results with the preceding quarter is set out below.

	Current Quarter	Preceding Quarter	Variance
for the financial period ended	30.6.2026	31.3.2026	
	(RM'000)	(RM'000)	(RM'000)
Revenue	2,550	2,654	(104)
Profit/(Loss) before tax	599	1,081	(482)

The Group recorded revenue of RM2.55 million in the current period, representing a decrease of RM0.10 million compared to RM2.65 million recorded in the preceding quarter. The reduction was mainly attributable to slightly lower demand for the Group's immunotherapy and cell therapies segments.

The Group recorded a profit before tax of RM0.60 million in the current quarter, compared to a profit before tax of 1.08 million in the preceding quarter. The decrease in profit before tax was mainly attributable to higher purchases and operating expenses incurred during the current quarter. The Group increased its production activities in anticipation of orders for the subsequent months, resulting in higher purchases during the quarter. In addition, the Group incurred higher administrative expenses, including staff costs, repairs and maintenance of assets as well as marketing expenses.

iii Prospects of the Group

Malaysian Genomics Resource Centre Berhad ("MGRC" or "The Group") is well-positioned to be a leading provider of genetic screening, genome analysis, and biopharmaceutical products and services in Southeast Asia. Utilising its high-throughput sequencing lab, advanced microarray facility, and state-of-the-art BSL-2 cell processing lab that is CGMP approved by MOH for production of cell and gene therapies, including immunotherapy for various types of cancer, the Group is committed to improving access to the latest in precision and personalised healthcare solutions for patients.

The Group's strategic move to reorganise its operations had led to the formation of four distinct verticals, each focused on addressing the multi-dimensional needs of the healthcare sector which are clinical testing and biotherapeutics, specialised healthcare services, specialised manufacturing and healthcare artificial intelligence and big data.

The Group's broad market access and diverse product portfolio have never been greater than they are today. An integral part of this requires increasing the breadth and depth of distribution networks for the Group's products and services. To this end, MGRC seeks and engages with strategic partners across Southeast Asia, the Middle-East North Africa region and the United States. To capitalise on its growing distribution network, the Group is applying its genomics and pharmaceutical expertise to develop a portfolio of products for the fast-moving consumer goods market. This includes novel ingredients and finished products for cosmeceuticals, wound healing, and genetic-based fitness improvement programs. In Malaysia, the Group works closely with private hospitals and the Ministry of Health to improve access to its immunotherapies.

iv Variance from Profit Forecast

The Group did not publish any profit forecast.

v Taxation

There was no taxation provided for the period.

vi Status of Corporate Proposal

There is no corporate proposal announced but pending completion as at the date of this announcement.

C Explanatory Notes Pursuant to Appendix 9B, of the Listing Requirements (cont.)
vii Material Litigations

As at the date of this announcement, there is no material litigation against the Group or taken by the Group.

viii Dividends

There were no dividends paid for the financial period.

ix Trade and Other Receivables
a. Trade Receivables

The ageing analysis of the Group's trade receivables is as follows:-

	30.6.2026 (RM'000)
Not past due	202
Past due	
- 1 to 30 days	70
- 31 to 60 days	34
- 61 to 90 days	43
- more than 90 days	9,991
	10,138
Gross	10,340
Impaired	(7,778)
Net	2,562

Receivables that are past due but not impaired

The Group believes that no further impairment allowance is necessary in respect of these trade receivables. They are substantially companies with good collection track record and no recent history of default.

b. Other Receivables

	30.6.2026 (RM'000)
Other receivables, deposits, advance to suppliers	11,996
Less: Expected credit losses	(6,746)
	5,250
Total Trade and Other Receivables	7,812

x EPS/(LPS)

- a) **Basic EPS/(LPS)** Computed by dividing the profit/(loss) after tax, attributable to owners of the parent for the financial period by the weighted average of the number of ordinary shares in issue during the period.

Basic EPS/(LPS)	Individual Quarter		Year-to-Date	
	Current Year	Previous Year	Current Year	Previous Year
for the financial period ended	30.6.2026	30.6.2025	30.6.2026	30.6.2025
Profit/(Loss) after tax, attributable to owners of the parent (RM'000)	660	(370)	1,800	(1,118)
Weighted average number of ordinary shares in issue ('000)	150,931	137,210	147,748	137,210
Basic EPS/(LPS) (sen)	0.44	(0.27)	1.22	(0.81)

- b) **Diluted EPS/(LPS)**. The Company does not have any convertible shares or convertible financial instruments for the current financial quarter and financial period to date.

C Explanatory Notes Pursuant to Appendix 9B, of the Listing Requirements (cont.)
xi Status of Utilisation of Proceeds

a)	Proposed utilisation of proceeds from private placement	Proposed utilisation timeframe	Proposed Utilisation (RM'000)	Variation (RM'000)	Actual Utilisation (RM'000)	Balance of Amount Allocated (RM'000)
	Future viable investment	Within 24 months from completion	3,620	(60)	(2,560)	1,000
	Working capital*	Within 12 months from listing	413	-	(413)	-
	Estimated expenses	Upon completion	-	60	(60)	-
			<u>4,033</u>	<u>-</u>	<u>(3,033)</u>	<u>1,000</u>

* In the event the Company is unable to identify any suitable and viable opportunities within the timeframe stipulated (or any extended timeframe, if applicable), the proceeds allocated for future viable investments shall be utilised as working capital of the Group.

b)	Proposed utilisation of proceeds from private placement	Proposed utilisation timeframe	Proposed Utilisation (RM'000)	Variation (RM'000)	Actual Utilisation (RM'000)	Balance of Amount Allocated (RM'000)
	Working capital	Within 24 months from completion	2,219	-	(1,527)	692
	Estimated expenses	Upon completion	265	-	(239)	26
			<u>2,484</u>	<u>-</u>	<u>(1,766)</u>	<u>718</u>

xii Authorisation for Issue

The interim financial statements were approved and authorised for issue by the Board of Directors of MGRC on 27 August 2026.